KR20200005576A - 호모타우린 및 이의 염의 제형 - Google Patents

호모타우린 및 이의 염의 제형 Download PDF

Info

Publication number
KR20200005576A
KR20200005576A KR1020197035170A KR20197035170A KR20200005576A KR 20200005576 A KR20200005576 A KR 20200005576A KR 1020197035170 A KR1020197035170 A KR 1020197035170A KR 20197035170 A KR20197035170 A KR 20197035170A KR 20200005576 A KR20200005576 A KR 20200005576A
Authority
KR
South Korea
Prior art keywords
pellet
hpmc
less
weight
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197035170A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 존스
케네스 페이
바드리나트 도니파르티
Original Assignee
컨플루언스 파마슈티컬스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 컨플루언스 파마슈티컬스, 엘엘씨 filed Critical 컨플루언스 파마슈티컬스, 엘엘씨
Publication of KR20200005576A publication Critical patent/KR20200005576A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197035170A 2017-05-17 2018-05-17 호모타우린 및 이의 염의 제형 Ceased KR20200005576A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762507532P 2017-05-17 2017-05-17
US62/507,532 2017-05-17
US201862660690P 2018-04-20 2018-04-20
US62/660,690 2018-04-20
PCT/US2018/033205 WO2018213589A1 (en) 2017-05-17 2018-05-17 Formulations of homotaurines and salts thereof

Publications (1)

Publication Number Publication Date
KR20200005576A true KR20200005576A (ko) 2020-01-15

Family

ID=64274653

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197035170A Ceased KR20200005576A (ko) 2017-05-17 2018-05-17 호모타우린 및 이의 염의 제형

Country Status (8)

Country Link
US (1) US12042566B2 (https=)
EP (1) EP3624788A4 (https=)
JP (2) JP2020519669A (https=)
KR (1) KR20200005576A (https=)
AU (2) AU2018269557B2 (https=)
IL (1) IL270654B2 (https=)
WO (1) WO2018213589A1 (https=)
ZA (1) ZA201908264B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270654B2 (en) 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof
WO2025163673A1 (en) * 2024-01-29 2025-08-07 Micro Labs Limited Dose-dumping resistant tablets of acamprosate calcium

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01280192A (ja) 1988-10-25 1989-11-10 Nichibei Co Ltd ブラインド内装サッシ
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
DE1073432T1 (de) 1998-04-14 2002-02-07 The General Hospital Corp., Boston Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
WO2000018374A1 (en) 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20050042277A1 (en) 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
CA2504471A1 (en) * 2004-06-18 2005-12-18 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
JP2010532331A (ja) 2007-07-05 2010-10-07 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 抗痙攣医薬組成物
CA2781830C (en) 2009-02-12 2018-03-27 Indiana University Research & Technology Corporation Materials and methods for treating developmental disorders including comorbid and idiopathic autism
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9195775B2 (en) 2009-06-26 2015-11-24 Iii Holdings 2, Llc System and method for managing and/or rendering internet multimedia content in a network
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
MX346203B (es) * 2010-09-28 2017-03-09 Depomed Inc Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior.
TR201809351T4 (tr) 2011-03-01 2018-07-23 Pharnext Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi.
DK3272342T3 (da) 2011-03-23 2021-06-07 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse
JP5893135B2 (ja) 2011-06-28 2016-03-23 ビボゾーン インコーポレイテッド 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2013293167B2 (en) 2012-07-22 2019-04-18 Indiana University Research And Technology Corporation Modulation sAPP, sAPP alpha and BDNF levels in individuals diagnosed with FXS and ASD
US20140073678A1 (en) 2012-09-12 2014-03-13 Monosol Rx, Llc Anti-pain and anti-nausea and/or vomiting combinatorial compositions
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2015217796B2 (en) 2014-02-11 2020-04-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
SG11201708393UA (en) * 2015-05-04 2017-11-29 Confluence Pharmaceuticals Llc Sprinkle formulations of acamprosate
HK1255584A1 (zh) 2015-08-04 2019-08-23 Confluence Pharmaceuticals, Llc 使用阿坎酸及d-环丝胺酸的联合疗法
JP6066009B1 (ja) 2016-06-16 2017-01-25 富士電機株式会社 ガス絶縁開閉装置用操作器及びそれを用いたガス絶縁開閉装置
IL270654B2 (en) 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof

Also Published As

Publication number Publication date
ZA201908264B (en) 2022-03-30
JP7499539B2 (ja) 2024-06-14
EP3624788A4 (en) 2021-03-03
AU2021225172B2 (en) 2023-04-06
IL270654B2 (en) 2024-07-01
US20200163895A1 (en) 2020-05-28
US12042566B2 (en) 2024-07-23
IL270654A (en) 2020-01-30
AU2018269557B2 (en) 2021-06-03
JP2020519669A (ja) 2020-07-02
EP3624788A1 (en) 2020-03-25
IL270654B1 (en) 2024-03-01
WO2018213589A1 (en) 2018-11-22
JP2023099100A (ja) 2023-07-11
CA3062834A1 (en) 2018-11-22
AU2021225172A1 (en) 2021-09-30
AU2018269557A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
US20100047343A1 (en) Multiparticulate formulation having tramadol in immediate and controlled release form
RU2467750C2 (ru) Ниацинсодержащие фармацевтическая композиция (варианты) и таблеточный препарат (варианты), способ снижения гиперемии и способ приготовления ниацинсодержащей таблетки
JP6796132B2 (ja) 液体剤形中の薬学的活性化合物放出性多層微小粒子
JP2021155434A (ja) アカンプロサートのスプリンクル製剤
TW201041607A (en) Orally disintegrating tablet compositions comprising combinations of non-opioid and opioid analgesics
US11883537B2 (en) Sustained release solid dosage forms for modulating the colonic microbiome
JP7499539B2 (ja) ホモタウリンおよびその塩の製剤
KR102568681B1 (ko) 네포팜을 포함하는 경구 붕해 약학 조성물 및 그 제조 방법
US12472149B2 (en) Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
CA3062834C (en) Formulations of homotaurines and salts thereof
JP7814075B1 (ja) 錠剤
RU2833481C2 (ru) Распадающаяся в ротовой полости фармацевтическая композиция, содержащая нефопам, и способ ее получения
RU2744270C2 (ru) Прессованный фармацевтический препарат
JP6150564B2 (ja) 口腔内速崩壊性錠剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191127

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210513

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230520

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240322

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230520

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I